Results 211 to 220 of about 164,975 (264)
Some of the next articles are maybe not open access.
IMMUNOPHARMACOLOGY OF RAPAMYCIN
Annual Review of Immunology, 1996▪ Abstract  The potent immunosuppressive drugs FK506 and rapamycin interfere with signal transduction pathways required for T cell activation and growth. The distinct inhibitory effects of these drugs on the T cell activation program are mediated through the formation of pharmacologically active complexes with members of a family of intracellular ...
R T, Abraham, G J, Wiederrecht
openaire +2 more sources
Blood distribution of rapamycin
Clinical Biochemistry, 1993Rapamycin (RAPA) is a potent new immunosuppressive drug. Although blood concentration monitoring of RAPA is being performed in preclinical and clinical trials, little is known regarding the blood distribution of the drug. Such information would have an impact on the medium used for analysis of the drug.
R, Yatscoff +3 more
openaire +2 more sources
Mechanisms of resistance to rapamycins
Drug Resistance Updates, 2001Rapamycins represent a novel family of anticancer agents, currently including rapamycin and its derivatives, CCI-779 and RAD001. Rapamycins inhibit the function of the mammalian target of rapamycin (mTOR), and potently suppress tumor cell growth by arresting cells in G1 phase or potentially inducing apoptosis of cells, in culture or in xenograft tumor ...
S, Huang, P J, Houghton
openaire +2 more sources
Rapamycin (sirolimus, rapamune)
Current Opinion in Nephrology and Hypertension, 1995Rapamycin is a novel immunosuppressive agent that is undergoing clinical trials for use in allograft rejection therapy. This paper reviews its in-vitro biological properties, the current state of knowledge concerning its mechanism of action, and its therapeutic applications.
S N, Sehgal +3 more
openaire +2 more sources
Swinging the vote for rapamycin
Nature Reviews Cancer, 2002Abstract Immunosuppressive drugs are commonly used to prevent immunological graft rejection in organ transplant recipients, but these have many serious side effects, including increasing the patient's risk for developing cancer. Cancer is, in fact, one of the main causes of death in organ transplant recipients.
openaire +2 more sources
Rapamycin targets STAT3 and impacts c-Myc to suppress tumor growth
Cell Chemical Biology, 2022Yaoyang Zhang, Yunxia Li, Yu Yan
exaly
Rapamycin: Therapeutic range investigations
Clinical Biochemistry, 1993R Yatscoff, N Kneteman, J Fryer
openaire +1 more source